Interactive chart
  • 1d
  • 5d
  • 1m
  • 6m
  • YTD
  • 1y
  • 2y
  • 5y
  • 10y
  • Max
Prev CloseN/A
BidN/A x N/A
AskN/A x N/A
52wk Rangeundefined - undefined
Day's RangeN/A - N/A
Avg Vol (3m)N/A
  • Zacks Small Cap Research5 months ago

    ARLZ: A Strong Management Team and Plenty of Capital Makes Aralez a Top Specialty Pharmaceutical Pick…

    On February 5, 2015, Aralez Pharmaceuticals Inc. (ARLZ) announced that the planned merger between Pozen, Inc. and Tribute Pharmaceuticals Canada, Inc. was complete following approval by the shareholders of each company. The strategy behind Aralez is that the company will become a cardiovascular focused specialty pharmaceutical company with support from a pain-focused franchise. As a reminder, in conjunction with the completion of the merger, a group of leading healthcare investors, led by Deerfield Management, has committed up to $350 million in capital for Aralez to fund the anticipated commercial launch of YOSPRALA® and for “future acquisitions”.

  • Insider Monkey6 months ago

    Billionaire Steven Cohen Reveals Two New Stock Picks, While Roberto Mignone Boosts Chimerix Inc. (CMRX) Stake

    The hedge fund industry as a whole did not perform particularly well in 2015, but there were a few investment vehicles that managed to greatly outperform the broader market. Steven Cohen’s family office Point72 Asset Management was one of those, as it gained almost 16% last year, while the S&P 500 Index closed the year in negative […]